Myovant Sciences
MYOV
MYOV was delisted on the 9th of March, 2023.
42 hedge funds and large institutions have $575M invested in Myovant Sciences in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 18 closing their positions.
6% more capital inflows, than outflows
Capital inflows: $16.9M | Capital outflows: $15.9M
0.07% more ownership
Funds ownership: 81.52% → 81.59% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
13% less funds holding
Funds holding: 48 → 42 (-6)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$5.69M |
| 2 |
Eventide Asset Management
Boston,
Massachusetts
|
+$3.16M |
| 3 |
Emory University
Atlanta,
Georgia
|
+$1.6M |
| 4 |
Millennium Management
New York
|
+$1.31M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.55M |
| 2 |
Deerfield Management
New York
|
-$3.77M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
-$1.98M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.38M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$981K |
MYOV Hedge Fund Activity: Q2 2017 in Review
42 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Myovant Sciences (MYOV) for Q2 2017, worth a combined $575M — down 0.22% from $577M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MYOV and 12 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was RA Capital Management, adding an estimated $5.69M. The largest seller was BlackRock, cutting an estimated $4.55M.
- 42 institutional investors held Myovant Sciences (MYOV) as of Q2 2017, down from 48 in Q1 2017.
- Funds reported $575M of Myovant Sciences stock for Q2 2017, down 0.22% quarter-over-quarter.
- 12 funds opened new Myovant Sciences positions in Q2 2017 and 18 closed out, a net change of -6 holders.
- The largest Myovant Sciences buyer in Q2 2017 was RA Capital Management, an estimated $5.69M added.
- The largest Myovant Sciences seller in Q2 2017 was BlackRock, an estimated $4.55M sold.
Based on aggregated 13F filings for Q2 2017.